Baseline characteristics
| Variable | Total (n=90) | CRSgrade0–1†(n=46) | CRS grade 2–5† (n=44) |
| Age, mean (SD) | 61.0 (10.9) | 59.6 (12.7) | 62.3 (8.5) |
| Sex, n (%) | |||
| Male | 52 (57.8%) | 27 (58.7%) | 25 (56.8%) |
| Female | 38 (42.2%) | 19 (41.3%) | 19 (43.2%) |
| Race, n (%) | |||
| White | 85 (94.4%) | 42 (91.3%) | 43 (97.7%) |
| Other† | 5 (5.6%) | 4 (8.7%) | 1 (2.3%) |
| BMI, mean (SD) | 29.0 (6.5) | 28.0 (6.2) | 30.0 (6.6) |
| BMI, n (%) | |||
| <25 | 25 (27.8%) | 15 (32.6%) | 10 (22.7%) |
| 25–29.9 | 35 (38.9%) | 20 (43.5%) | 15 (34.1%) |
| ≥30 | 30 (33.3%) | 11 (23.9%) | 19 (43.2%) |
| Other baseline traditional CVD risk factors, n (%) | |||
| DM | 19 (21.1%) | 8 (17.4%) | 11 (25.0%) |
| MI | 1 (1.1%) | 0 (0%) | 1 (2.3%) |
| CAD | 7 (7.8%) | 4 (8.7%) | 3 (6.8%) |
| CKD (stage IV or V) | 4 (4.4%) | 3 (6.5%) | 1 (2.3%) |
| CHF | 8 (8.9%) | 4 (8.7%) | 4 (9.1%) |
| AF | 10 (11.1%) | 5 (10.9%) | 5 (11.4%) |
| Smoking status, n, (%) | |||
| Never | 43 (47.8%) | 27 (58.7%) | 16 (36.4%) |
| Previous | 38 (42.2%) | 15 (32.6%) | 23 (52.3%) |
| Current | 9 (10.0%) | 4 (8.7%) | 5 (11.4%) |
| Primary malignancy, n (%) | |||
| DLBCL | 85 (94.4%) | 43 (93.5%) | 42 (95.5%) |
| FL | 2 (2.2%) | 2 (4.3%) | 0 (0%) |
| MCL | 3 (3.3%) | 1 (2.2%) | 2 (4.5%) |
| Disease response at time of CAR-T | |||
| Relapse | 62 (68.9%) | 31 (67.4%) | 31 (72.7%) |
| Primary refractory | 28 (31.1%) | 15 (32.6%) | 13 (29.5%) |
| Ann Arbor stage, n (%) | |||
| 0 | 0 (0%) | 0 (0%) | 0 (0%) |
| 1 | 4 (4.4%) | 3 (6.5%) | 1 (2.3%) |
| 2 | 9 (10.0%) | 2 (4.3%) | 7 (15.9%) |
| 3 | 23 (25.6%) | 14 (30.4%) | 9 (20.5%) |
| 4 | 40 (44.4%) | 21 (45.7%) | 19 (43.2%) |
| Unknown | 14 (15.6%) | 6 (13.0%) | 8 (18.2%) |
| International Prognostic Index (IPI) score, risk stratification, n (%) | |||
| 0–1 | 9 (10.0%) | 6 (13.0%) | 3 (6.8%) |
| 2 | 12 (13.3%) | 7 (15.2%) | 5 (11.4%) |
| 3 | 9 (10.0%) | 4 (8.7%) | 5 (11.4%) |
| 4–5 | 9 (10.0%) | 6 (13.0%) | 3 (6.8%) |
| Unknown | 51 (56.7%) | 23 (50.0%) | 28 (63.6%) |
| Bulky disease | 51 (56.7%) | 27 (58.7%) | 24 (54.5%) |
| Genetic mutations, stratification, n (%) | |||
| Double hit: Del-Myc and (BCL2 or BCL6) | 24 (26.7%) | 10 (21.7%) | 14 (31.8%) |
| Triple hit: Del-Myc, BCL2, BCL6 | 2 (2.2%) | 0 (0%) | 2 (4.5%) |
| Transformed (low grade to high grade) | |||
| Yes | 30 (33.3%) | 14 (30.4%) | 16 (36.4%) |
| No | 60 (66.7%) | 32 (69.6%) | 28 (63.6%) |
| Baseline ECOG performance status, n (%) | |||
| 0 | 39 (43.3%) | 20 (43.5%) | 19 (43.2%) |
| 1 | 44 (48.9%) | 24 (52.2%) | 20 (45.5%) |
| 2 | 6 (6.7%) | 2 (4.3%) | 4 (9.1%) |
| 3 | 0 (0%) | 0 (0%) | 0 (0%) |
| 4 | 0 (0%) | 0 (0%) | 0 (0%) |
| Unknown | 1 (1.1%) | 0 (0%) | 1 (2.3%) |
| Treatment history, n (%) | |||
| Number of prior anticancer therapies, median (IQR) | 3 (2–4) | 3 (2–3) | 3 (2–4) |
| Prior anthracycline | 85 (94.4%) | 42 (91.3%) | 42 (95.5%) |
| Kymriah (tisagenlecleucel) | 32 (35.6%) | 22 (47.8%) | 10 (22.7%) |
| Yescarta (axicabtagene ciloleucel) | 55 (61.1%) | 23 (50.0%) | 32 (72.7%) |
| Tecartus (brexucabtagene autoleucel) | 3 (3.3%) | 1 (2.2%) | 2 (4.5%) |
| Prior chemotherapy | 90 (100%) | 46 (100%) | 44 (100%) |
| Prior targeted therapy | 90 (100%) | 46 (100%) | 44 (100%) |
| Prior immunomodulatory (eg, checkpoint inhibitor) | 4 (4.4%) | 4 (8.7%) | 0 (0%) |
| Prior autologous stem cell transplantation | |||
| Baseline SBP (mm Hg) | |||
| <100 | 0 (0%) | 0 (0%) | 0 (0%) |
| 100–119 | 31 (34.4%) | 14 (30.4%) | 17 (38.6%) |
| 120–129 | 28 (31.1%) | 17 (37.0%) | 11 (25.0%) |
| 130–139 | 13 (14.4%) | 6 (13.0%) | 7 (15.9%) |
| 140–179 | 18 (20.0%) | 9 (19.6%) | 9 (20.5%) |
| 180+0 (0%)0 (0%)0 (0%) | |||
| Baseline DBP (mm Hg) | |||
| <60 | 13 (14.4%) | 6 (13.0%) | 7 (15.9%) |
| 60–69 | 34 (37.8%) | 13 (28.3%) | 21 (47.7%) |
| 70–79 | 27 (30.0%) | 19 (41.3%) | 8 (18.2%) |
| 80–89 | 14 (15.6%) | 8 (17.4%) | 6 (13.6%) |
| 90–119 | 2 (2.2%) | 0 (0%) | 2 (4.5%) |
| 120+0 (0%)0 (0%)0 (0%) | |||
| Baseline anti-HTN medications | |||
| Beta-blocker | 17 (18.9%) | 10 (21.8%) | 7 (15.9%) |
| ACE inhibitor/ARB | 21 (23.3%) | 9 (19.6%) | 12 (27.3%) |
| Calcium channel blocker | 12 (13.3%) | 6 (13.0%) | 6 (13.6%) |
| Diuretic† | 11 (12.2%) | 6 (13.0%) | 5 (11.4%) |
*Black, Hispanic, Asian, multiracial, and unknown race.
†Includes loop, thiazide, and potassium-sparing diuretics.
ACE, angiotensin converting enzyme inhibitor; AF, atrial fibrillation; BCL, B-cell lymphoma; BMI, body-mass-index; CAD, coronary artery disease; CAR-T, chimeric antigen receptor T-cell; CHF, congestive heart failure; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DLBCL, diffuse large B-cell lymphoma; DM, diabetes mellitus; ECOG, Eastern Co-operative Oncology Group; FL, follicular lymphoma; HTN, hypertension; MCL, mantle cell lymphoma; MI, myocardial infarction; Myc, myelocytomatosis viral oncogene homolog; SBP, systolic blood pressure.;